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Potent organometallic osmium compounds
induce mitochondria-mediated apoptosis and
S-phase cell cycle arrest in A549 non-small
cell lung cancer cells
Sabine H. van Rijt,a Isolda Romero-Canelo´n,a Ying Fu,a Steve D. Shnyderb and
Peter J. Sadler*a
The problems of acquired resistance associated with platinum drugs may be addressed by
chemotherapeutics based on other transition metals as they oﬀer the possibility of novel mechanisms of
action. In this study, the cellular uptake and induction of apoptosis in A549 human non-small cell
lung cancer cells of three promising osmium(II) arene complexes containing azopyridine ligands,
[Os(Z6-arene)( p-R-phenylazopyridine)X]PF6, where arene is p-cymene or biphenyl, R is OH or NMe2,
and X is Cl or I, were investigated. These complexes showed time-dependent (4–48 h) potent anticancer
activity with highest potency after 24 h (IC50 values ranging from 0.1 to 3.6 mM). Cellular uptake of the
three compounds as quantified by ICP-MS, was independent of their logP values (hydrophobicity).
Furthermore, maximum cell uptake was observed after 24 h, with evident cell efflux of the osmium
after 48 and 72 h of exposure, which correlated with the corresponding IC50 values. The most active
compound 2, [Os(Z6-p-cymene)(NMe2-phenylazopyridine)I]PF6, was taken up by lung cancer cells pre-
dominately in a temperature-dependent manner indicating that energy-dependent mechanisms are
important in the uptake of 2. Cell fractionation studies showed that all three compounds accumulated
mainly in cellular membranes. Furthermore, compound 2 induced apoptosis and caused accumulation
in the S-phase of the cell cycle. In addition, 2 induced cytochrome c release and alterations in mito-
chondrial membrane potential even after short exposure times, indicating that mitochondrial apoptotic
pathways are involved. This study represents the first steps towards understanding the mode of action of
this promising class of new osmium-based chemotherapeutics.
Introduction
Lung cancer is the leading cause of cancer deaths in the
Western World. Survival rates are poor with a 5-year mortality
of about 90%. Most patients face an intensive and invasive
treatment regimen comprising surgery, chemotherapy, or radio-
therapy, often combinations thereof.1 The platinum-based drug,
cisplatin (CDDP) is a commonly used chemotherapeutic agent
for the treatment of lung cancer. However, one of the major
drawbacks of CDDP is acquired resistance of tumours towards
the drug. To overcome this problem, CDDP is often given as a
combination treatment with other chemotherapeutics such as
etoposide, gemcitabine or paclitaxel.2,3 Anticancer drugs based
on other transition metals may address the problems asso-
ciated with acquired resistance to platinum drugs. Several other
metal-based compounds with promising antitumor activity
towards a wide range of tumours with novel mechanisms of
action have been reported.4–7 In recent years, we and others
have reported organometallic osmium(II) arene complexes with
promising cancer cell cytotoxicity.8–11 Some of these osmium
complexes are non-cross-resistant with CDDP toward some
cancer cells,8,12,13 suggesting that they have a different mecha-
nism of action and show potential for addressing the problem
of intrinsic or acquired resistance towards CDDP. A particularly
promising class of osmium(II) arene complexes containing
azopyridine (azpy) ligand derivatives, [Os(Z6-arene)( p-R-phenyl-
azopyridine)X]PF6, where arene is p-cymene or biphenyl, and
X is Cl or I, show nanomolar activity towards a large panel of
cancer cell lines.8 In addition, some of these complexes exhibit
low toxicity and negligible deleterious effects in a colon cancer
tumour xenograft model, indicating that they may have a broad
therapeutic window.14 Interestingly, the toxicity of these
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complexes can be modulated by manipulation of intracellular
GSH levels. Antiproliferative activity can be partly inhibited by
increasing GSH levels prior to drug exposure by pre-treating the
cells with N-acetyl-L-cysteine, one of the precursors of GSH.8,15
In contrast, the potency of these metal-based compounds can
be increased by co-administration of L-buthionine sulfoximine
(L-BSO) which inhibits the synthesis of GSH.16
In this study, three compounds containing phenylazo-
pyridine (azpy) ligands with dimethylaminyl (NMe2) or hydroxyl
(OH) substitutions on the phenyl ring and iodido or chlorido
leaving groups; [Os(Z6-bip)( p-OH-azpy)I]PF6 (1), [Os(Z
6-p-cym)-
( p-NMe2-azpy)I]PF6 (2), and [Os(Z
6-p-cym)( p-NMe2-azpy)Cl]PF6
(3) where bip is biphenyl and p-cym is p-cymene, were investi-
gated in the A549 human non-small cell lung cancer cell line
(Fig. 1). The structures of the complexes allow a comparison
between the diﬀerent leaving groups and substitutions on the
pyridine ring. These complexes have already been shown to
have nanomolar activity in ovarian, breast, colon, prostate and
bladder human cancer cell lines.8 Here we show that three of
them have potent activity in A549 cells that is dependent on
exposure time. The mechanism by which A549 cells take up
and internalize the osmium arene compounds is investigated
by studying the time- and temperature-dependence of cell
uptake, their hydrophobicity, and intracellular localisation.
Moreover, the involvement of the mitochondrial apoptotic
pathway in the induction of apoptosis by the most potent
complex 2 is studied. This work represents the first steps
towards understanding the mode of action of this promising
class of chemotherapeutic agents.
Experimental
Materials
1,4-Dihydrobiphenyl and the dimers [(Z6-p-cym)OsCl2]2 and
[(Z6-bip)OsCl2]2 were prepared by previously reported procedures.
17
OsCl3nH2O was purchased from Alfa Aesar. All deuterated solvents
and CDDP were obtained from Sigma Aldrich. Methanol was
distilled over magnesium–iodine prior to use. Complexes 1–3
were synthesized and characterized as reported previously.8
ICP-MS instrumentation and calibration
ICP-MS analyses were carried out on an Agilent Technologies
7500 Series ICP-MS instrument. The water used for ICP-MS analysis
was double deionised (DDW) using a USF Elga UHQwater deionizer.
The osmium Specpure plasma standard (Alfa Aesar, 1000 ppm in
5% HCl) was diluted with DDW to 20 ppm. The standards for
calibration were freshly prepared by diluting this stock solution with
3% HNO3 in DDW. The concentrations used were 100, 60, 20, 10, 5,
4, 2, 1, 0.4 and 0.1 ppb. The detection limit was typically 30 ppt
(n = 10), and sensitivity 42200 189Os ion counts for 100 ppb of
Os standard in helium mode and 9 ppt (n = 10), and sensitivity
270900 189Os ion counts for 100 ppb of Os standard in no gasmode.
Cell culture
The human A549 non-small cell lung cancer cell line was
obtained from the ECACC (European Collection of Animal Cell
Culture, Salisbury, UK) and used between passages 5 and 15.
The cells were maintained in RPMI 1640 media which was
supplemented with 10% fetal calf serum, 1% L-glutamine and
1% penicillin/streptomycin. All cells were grown at 310 K in a
humidified atmosphere containing 5% CO2, and passaged
routinely when 80% confluence was reached.
In vitro growth inhibition assay
After plating, A549 cells were treated with OsII complexes on day 2,
at concentrations ranging from 0.1 mM to 100 mM. Stock solutions
of the OsII complexes (1 mM) were made up in 0.125% (v/v) DMSO
to assist dissolution (0.03% final concentration of DMSOper well in
the 96-well plate). Negative controls were exposed to the same final
DMSO concentration. The osmium stock solutions were analysed
by ICP-MS to confirmmetal content, with working solutions diluted
from the stock solutions. Cells were exposed to the complexes for
4 h, 24 h, or 48 h, washed, supplied with fresh medium, allowed to
grow for three doubling times (72 h), and then the protein content
measured (proportional to cell survival) using the sulforhodamine
B (SRB) assay.18 We also determined the antiproliferative activity of
complex 2 under a second set of conditions which included seeding
the A549 cells in 6-well plates and allowing 24 h of pre-incubation
time in drug free-medium followed by 24, 48 or 72 h of drug
exposure at 310 K under humidified atmosphere. In this case, cells
were not allowed to recover and the SRB assay was performed upon
completion of the drug exposure period.
Drug uptake and cell fractionation
A549 cells were plated at a density of 3  106 cells per 100 mm
Petri dish in 12 mL of culture medium on day 1 (three dishes
Fig. 1 Chemical structures of the organometallic osmium(II) arene com-
plexes studied in this work.
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were prepared per compound tested and three untreated control
dishes in two independent set of experiments). On day 2 cells were
exposed to the OsII arene complexes. Stock solutions (0.5 mM) of
osmium compounds were made up fresh in 5% DMSO and saline
before being diluted in medium to give a final concentration of
1 mM (0.01% v/v final concentration of DMSO per well). Negative
controls were exposed to the same final DMSO concentration.
After 24 h of drug exposure, the drug-containing medium was
removed; the cells were washed with PBS, trypsinised and the cell
suspension counted. Half of the cells were centrifuged, washed
with PBS and stored at 253 K. The other half of the sample was
used for cytosol, nucleus, membrane and cytoskeleton fraction-
ation using the cell fractionation kit (Biovision, Mountain
View, US) (fractionPREPt) according to the manufacturer’s
instructions. All samples were stored at 253 K until ICP-MS
analysis for osmium content. For the time- and temperature-
dependent cell uptake experiments, A549 cells were plated at a
density of 3  106 cells per 100 mm Petri dish in 12 mL of
culture medium on day 1. On day 2 cells were exposed to
complex 2 at a concentration of 1 mM (prepared as stated
previously) at 0.5, 1, 2 and 4 h time intervals. After the indicated
exposure times, cells were trypsinized and the cell suspension
counted. The cells were centrifuged, washed with PBS and
stored at 253 K until ICP-MS analysis for osmium content.
ICP-MS analysis
The whole cell pellets and cytosol/nucleus/membrane/cytoskeleton
fractionation samples were digested as described below. To the cell
pellets was added 0.4 mL and to the extracts 0.2 mL of freshly
distilled 72% HNO3 and the samples were transferred into
wheaton v-vialss (Sigma Aldrich). The vials were heated in an
oven at 373 K for 16 h to fully digest the samples, allowed to
cool, and then each sample was transferred to a falcon tube.
The vials were washed with DDW and the samples diluted
10 times with DDW to obtain 7.2% HNO3 sample solutions.
Live/dead assay using Annexin V
The induction of apoptosis or necrosis was investigated in A549
cells using Annexin V FITC and propidium iodide double
staining. Briefly, 2.5  105 cells were seeded per well in 6-well
plates. 24 h after seeding, control cells and cells treated with
compound 2 at the indicated concentrations were incubated for
24 and 48 h. Following exposure, the drug-containing medium
was removed, and cells were washed, harvested and stained
with Annexin V FITC and propidium iodide (Biovision, Annexin
V-FITC Apoptosis Kit) according to the manufacturer’s instructions.
Control samples stained with just PI or Annexin V FITC were also
included for compensation purposes. The samples were analysed
using FACS Caliburt flow cytometer running Cell Quest software
(20000 events were collected from each sample).
Cytochrome c release and mitochondrial membrane potential
assays
The release of cytochrome c into the cytosol of A549 cells
exposed to complex 2 was investigated using the FlowCellect
Cytochrome c Kit from Merk Millipore according to the
manufacturer’s instructions. Briefly, cells were seeded in tripli-
cate into 6-well plates and incubated in drug-free medium for
24 h before exposing them to complex 2 for 4 or 24 h. After the
drug exposure period, supernatants were removed by suction
and cells were washed with cold PBS before being trypsinized
and counted. Each sample was aliquoted into 500 mL of a PBS
solution containing 1.5  105 cells, permeabilized, fixed and
blocked before adding the anti-IgG1-FITC isotype control or the
anti-cytochrome c-FITC antibody to each sample. After further
blocking treatment, samples were analyzed in a Beckton Dickinson
FACScan. The reduction of green fluorescence in the FL1 channel
indicated the release of cytochrome c into the cytosol.
To determine the mitochondrial membrane potential by
microscopy, A549 cells were grown on chamber slides (Nunct
Lab-Tekt). 24 h after plating, the cells were treated with 2.5 mM
complex 2. After 24 or 48 h incubation with 2, the drug-
containing medium was removed, cells were washed and stained
with MitoCapture Apoptosis Detection Kit (Biovision) according
to the manufacturer’s instructions. The live cells were imaged on
a LEICA SP5 confocal microscope.
Cell cycle
A549 cells were seeded at a density of 2.5  105 cells per well in
a 6-well plate and grown for 24 h. After the 24 h, cells were
treated with complex 2 with the indicated concentrations. Cells
were collected after 24 or 48 h of incubation and washed with
PBS. Cells were fixed with 70% ethanol and stored at 253 K. For
analysis, cells were transferred into PBS, incubated with RNase
(0.2 mg mL1) and propidium iodide (0.05 mg mL1) for 40 min
at 310 K and then analysed by flow cytometry using a FACS
Caliburt flow cytometer as above. The resulting DNA histograms
were quantified using the FlowJo software (version 7.2.5).
Determination of partition coeﬃcient, logP
Octanol–saturated water (OSW), and water–saturated octanol
(WSO) were prepared using analytical grade octanol (Sigma)
and 0.3 M NaCl for chloride complex 3 and 0.3 M NaI solution
was used for the iodide complexes 1 and 2. Aliquots of stock
solutions of osmium complexes in OSW were added to equal
volumes of WSO and shaken in an IKA Vibrax VXC basic shaker
for 4 h at 500 g min1. After partition, the aqueous and octanol
layers were carefully separated into test tubes for osmium
analysis. Dilutions of the aqueous samples before and after
partitioning were made with 3% HNO3 to the appropriate range
for analysis by ICP-MS calibrated with aqueous standards
(Os: 1–100 ppb). These procedures were carried out at ambient
temperature (ca. 298 K). Partition coefficients of OsII arene
complexes were calculated using the equation log Poct =
log([Os]oct/[Os]aq).
Results and discussion
Synthesis
Osmium arene compounds 1–3 (Fig. 1) were prepared via their
respective I- or Cl-bridged dimers, [(Z6-arene)OsX2]2 where
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arene = biphenyl (bip) or p-cymene ( p-cym) and X = I or Cl, as
previously reported, with over 95% purity.8
Cytotoxicity
The anticancer activity of compounds 1–3 in A549 cells at
different exposure times (4, 24 and 48 h) was evaluated after
three doubling recovery times (72 h) in non-drug containing
medium (Table 1). The cytotoxicity of these compounds under
these conditions after 24 h has been reported by our laboratory
previously and the data obtained here demonstrated similar
activity.8 All three compounds showed potent activity with
IC50 values of between 0.17 and 35.7 mM. Compounds 1 and 2
especially showed high anticancer activity, on the order of
6–10more potent compared to cisplatin under the same testing
conditions. The IC50 values of the osmium compounds were
dependent on the exposure time, whereas the activity of CDDP
was unaffected over the period 4 to 48 h (Table 1). The highest
activity for all compounds was seen after 24 h of exposure; potency
follows the order 24 14 3where compound 2 is themost potent
with an IC50 value of 0.17 mM and complex 3, the chlorido
analogue of the iodido complex 2, is the least active. After 4 h
of cell exposure, iodido compounds 1 and 2 already show high
cytotoxic activity. After 48 h of exposure, the IC50 values of all three
compounds had increased. These compounds are known to be
stable under aqueous conditions,8 suggesting that the IC50 values
do not diminish over-time because of chemical decomposition.
These data suggest that optimisation of the incubation time for
this class of drugs is vital to obtain maximum cytotoxic activity.
Iodido compounds 1 and 2 show very similar toxicity despite their
different arenes (biphenyl and p-cymene) and substituents on the
phenyl ring (OH and NMe2, respectively). This, in combination
with the large difference in toxicity between complex 2 and its
chlorido analogue compound 3, suggests that for these complexes
the halido monodentate ligand plays an important role in the
mechanism of action. Indeed, we have previously reported
osmium complexes of the type [Os(Z6-arene)(azpy-R)I]PF6, where
changing the monodentate leaving group from chloride to iodide
had a dramatic effect on their potency.15,19 Interestingly, the
iodido osmium arene complexes are remarkably inert towards
ligand substitution which seems to indicate that the mechanism
of cytotoxicity involves ligand-based redox reactions.
The initial cytotoxicity assays were performed in 96-well plates
and included a 72 h recovery period in drug-free medium.
We also assayed the cytotoxicity of compound 2 under the
same culture conditions as were used for cell uptake, cell cycle
and apoptosis studies (i.e. larger culture plates and no recovery
period). The cytotoxicity of 2 was much lower under these
conditions (Fig. 2). This may be explained by the reduced drug-
to-cell ratio, and lack of opportunity for the cells to recover.
logP and cellular uptake
The octanol–water partition coefficient (log P value) is routinely
used to relate anticancer activity and hydrophobicity for (metal-
based) drugs. For several classes of anticancer metal complexes
Table 1 In vitro growth inhibition of A549 cells for complexes 1–3 and
cisplatin (CDDP) as control at different exposure times, values are given as
IC50 (mM). Cells were grown in 96-well plates and allowed to recover for
3 doubling times (72 h)
Compound
IC50
a (mM)
4 h 24 h 48 h
1 1.55  0.21 0.31  0.02 1.68  0.14
2 0.85  0.15 0.17  0.01 0.32  0.03
3 33.95  1.50 3.64  0.23 35.73  2.32
CDDP 1.92  0.11 1.78  0.15 1.79  0.25
a Each value represents themean SD for three independent experiments.
Fig. 2 In vitro growth inhibition for compound 2 in A549 cells after 4 and
24 h of exposure with cell culture conditions used for cell uptake, cell cycle
and apoptosis studies. Under these conditions there was no recovery period
included. In addition, increased cell numbers and decreased drug media
volumes were used compared to the experiment as reported in Table 1.
Fig. 3 Hydrophobicity and cellular uptake of compounds 1, 2 and 3.
(A) logP values for complexes 1–3. (B) Cellular osmium concentrations
determined in A549 cells after 24 h exposure to 1 mM of complex 1, 2
and 3. Results are mean of six independent experiments and are expressed
as mean  SD.
Paper Metallomics
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
6 
M
ar
ch
 2
01
4.
 D
ow
nl
oa
de
d 
on
 2
5/
10
/2
01
6 
14
:3
4:
46
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
1018 | Metallomics, 2014, 6, 1014--1022 This journal is©The Royal Society of Chemistry 2014
a positive correlation between hydrophobicity and cytotoxicity
has been reported.20–22 To assess the hydrophobicity of these
osmium complexes, the partition coefficients (log P) were deter-
mined in octanol–water containing 300 mM sodium chloride or
sodium iodide in order to suppress hydrolysis. The log P values
(Fig. 3A) increase in the order of 3 o 2 o 1 with values of
0.57  0.05 for 3, 0.30  0.01 for 2 and 0.26  0.03 for 1.
Next, the cellular uptake of compounds 1–3 after 24 h was
determined to assess whether the hydrophobicity of the com-
pounds (as measured by logP, Fig. 3A) correlated with the amount
of compound taken up by the cell. The highest intracellular
levels of osmium were observed after exposure to complex 1
(296.5  2.0 pmol Os per 106 cells) and 2 (307.8  38.9 pmol Os
per 106 cells), and much less for least hydrophobic complex 3
(112.2  31.2 pmol Os per 106 cells) (Fig. 3B). The cellular
uptake follows the order 1–24 3, which does not correlate with
their respective log P values (Fig. 3A and B). Surprisingly,
substituting the iodide (2) by chloride (3) results in ca. 3 times
less cellular uptake of osmium, indicating that the halogen
plays an important role in the mechanism of cell uptake for
these complexes. Although the log P values for 1 and 2 are quite
different they are taken up into cells to a similar extent. The
mechanism by which cellular uptake takes place needs to be
considered as well and so hydrophobicity may not be the only
parameter important for cellular uptake of these complexes. In
order to assess the importance of energy-dependent cellular
uptake mechanisms, the temperature dependence of the cellular
accumulation of complex 2 as a function of time (t = 1, 2 and 4 h)
Fig. 4 Time- and temperature-dependent cellular uptake of complex 2 in
A549 cells. (A) Cellular osmium concentrations determined after 0.5, 2 and
4 h exposure to 1 mM of complex 2 at 277 K and 310 K. (B) Cellular osmium
concentrations determined after 0.5, 2, 4, 24, 48 and 72 h exposure to
1 mM of complex 2. Results are mean of three independent samples and are
expressed as mean  SD.
Fig. 5 Cellular distribution. (A) Concentration (left panel) and percentage (right panel) of osmium accumulating in nucleus, cytosol, cytoskeleton and
membrane fractions in A549 lung cells after 24 h exposure to 1 mM of 1–3. (B) Concentration (left panel) and percentage (right panel) of osmium
accumulating in nucleus, cytosol, cytoskeleton and membrane fractions (pmol Os per 106 cells) in A549 cells after 24, 48 and 72 h exposure to 1 mM of 2.
Results are mean of three independent experiments and are expressed as mean  SD.
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was investigated (Fig. 4A). At the low temperature of 277 K,
complex 2 was taken up by the cells to a reduced extent
compared to the uptake observed at 310 K with levels of
37.8  0.5 pmol Os per 106 cells after 4 h at 277 K and
126.8  38.8 pmol Os per 106 cells at 310 K. This shows that
a quarter of the total Os taken up into the cells can be
attributed to passive diffusion (energy-independent routes),
and more than one mechanism is responsible for the uptake
of 2. We have observed a similar behavior for analogous Ru
half-sandwich complexes containing iminopyridine ligands.
In the latter case, the iodido derivatives were taken up partly
via passive diffusion, while this was not observed for the
chlorido derivatives.23 Other metal complexes are known to
be taken up partly via passive diffusion in addition to energy-
dependent routes, these include vanadium complexes,21 copper
bis(thiosemicarbazonato) complexes,24 and, bis(cyclometalated)
iridium(III) polypyridine complexes.25
The reduction of cell uptake of 2 by ca. 75% at lower tem-
peratures indicates that the uptake mechanism mainly involves
energy-dependent routes. It would be interesting to establish
which energy-dependent cell uptake route(s) is(are) responsible
for the cellular uptake of complex 2 and related compounds.
Such knowledge would aid the design of new compounds as
well as help clarify their mechanism of action. It is likely that
more pathways are involved, as observed previously for analogous
ruthenium complexes.23
To help explain the exposure-time dependence of IC50
values, the cellular uptake for 2, the most potent complex was
investigated as a function of time (t = 0.5, 2, 4, 24, 48 and 72 h)
(Fig. 4B). Cellular uptake was fast with significant uptake after
only 0.5 h of exposure, explaining the observed low IC50 values
after 4 h of exposure (Table 1). The maximum cell uptake was
reached after 24 h exposure (307.8  38.8 pmol Os per 106 cells),
while after 48 h and 72 h of exposure to 2, the amount of osmium
decreased markedly to 202.8  39.5 pmol Os per 106 cells and
108.5  5.6 pmol Os per 106 cells, respectively. This suggests that
cellular eﬄux is an important factor in the cellular processing of
these drugs and may arise from the activation of detox pumps
such as PgP after certain exposure times, as a mechanism for
cell recovery. This may explain why the IC50 values at longer
exposure times of 48 h are not as low as those found after only
24 h of exposure.
Cellular distributions
The distribution of the osmium in isolated cell fractions
(membrane, cytoskeleton, cytosol and nucleus) was determined
after 24 h exposure to complexes 1–3 (Fig. 5A). The cellular
distribution for all three compounds is very similar with 74–80%
of osmium content localising in the membrane, 4–15% in the
cytosol, 4–9% in the nucleus and 6–8% in the cytoskeleton
fraction (Fig. 5A, right panel). A surprisingly high amount of
osmium was detected in the membrane fraction, which also
includes mitochondrial membranes.
The cellular distribution of complex 2 was also studied over
the periods t = 24, 48 and 72 h (Fig. 5B). The overall amount of
osmium in the cells decreased significantly over time as was
observed in the uptake experiments of 2 in the whole cell (Fig. 5B).
Interestingly, the amount of osmium from 2 that had localised
in the nucleus and cytoskeleton remained approximately the same
(with values of 7.6–9.4 pmol Os per 106 cells and 9.8–14.8 pmol
Os per 106 cells, respectively), whereas the amount of osmium in
the cytosol and membrane fractions decreased after 72 h to about
half of the amount found after 24 h (with values of 33.6 4.8 pmol
Os per 106 cells after 24 h to 15.63 3.02 pmol Os per 106 cells after
72 h in the cytosol, and 164.3  30.4 pmol Os per 106 cells after
Fig. 6 Induction of apoptosis by compound 2. (A) Flow cytometric
analysis of apoptosis/necrosis cell death using Annexin V-FITC/PI staining
of A549 cells treated with complex 2. Percentages of cells in each quadrant
are given. Data are the representative of one of two individual experiments.
(B) The ability of complex 2 to induce cytochrome c release by determined
by FACS analysis. (C) Disruption of the mitochondrial membrane potential
at 24 and 48 h of drug exposure visualized by a cationic dye that fluoresces
diﬀerently in healthy cells (bright red) versus cells that contain mitochondria
with a disrupted membrane potential (green fluorescence in the cytosol).
Top row 20, bottom row 40 magnification.
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24 h and 92.2  16.12 pmol Os per 106 cells after 72 h in the
membrane) accounting for the efflux observed in the time-
dependent cell uptake studies.
Apoptosis
The ability of compound 2 to promote apoptosis/necrosis in
A549 cells was determined by flow cytometry after staining the
cells with Annexin-V-FITC and propidium iodide (PI). Externa-
lisation of PS (phosphatidylserine) from the inner face of the
plasma membrane to the cell surface is a hallmark of early
apoptosis. The FITC labelled Annexin-V binds to PS, resulting
in green fluorescence of early apoptotic cells. In later stages of
apoptosis, PI enters the cell and binds strongly to DNA result-
ing in a strong red fluorescence. Cells in later apoptotic phases
will therefore have both green and red fluorescence. Treatment
of the A549 cells with compound 2 for 24 h or 48 h resulted in
an increase in late stage apoptotic cells (upper right quadrant
corner in Fig. 6A). None of the treated cells were necrotic
(containing just PI staining, upper left quadrant) and few cells
were in the early apoptotic stage (just Annexin-V-FITC staining,
lower right quadrant). These data therefore show that com-
pound 2 induces cell death via apoptotic pathways and does not
induce necrosis.
Mitochondria-induced apoptosis
Since we observed a high amount of drug accumulation in the
cell membrane fractions and since these fractions contain a
large quantity of mitochondrial membranes, we next investi-
gated whether the most potent anticancer compound (2) acts
on mitochondrial pathways.
Cytochrome c is released from mitochondria during the early
stages of apoptosis and is a central event in apoptotic signalling.26
The ability of compound 2 to induce the release of cytochrome c
was investigated at early time-points (4 and 24 h). After 4 h,
compound 2 was able to induce cytochrome c release even at
the lowest dose tested of 1 mM (Fig. 6B). Previously no cell death
was observed at any of the doses tested at 4 h (Fig. 2), indicating
that compound 2 is already acting on mitochondria at low non-
toxic doses, at early time-points prior to phenotypic detection of
cell death. Also after 24 h, an induction of cytochrome c release
could be observed after exposure to the lowest dose of 1 mM.
Moreover, at the highest dose tested (10 mM) an additional peak
due to the appearance of an apoptotic cell population was
visible (Fig. 6B).
Next we assessed whether compound 2 was also able to alter
the mitochondrial transmembrane potential, another measure
for mitochondrial health. Disruption of the mitochondrial
membrane potential could be observed with confocal micro-
scopy by the use of Mitotracker, a dye that can only aggregate in
healthy mitochondria, fluorescing red. In apoptotic cells, the
dye cannot aggregate in the mitochondria and remains in the
cytosol, fluorescing green. In the control cells most of the dye
had accumulated in the mitochondria giving oﬀ a bright red
fluorescence, showing that the cells had healthy mitochondria
(Fig. 6C). Cells treated with complex 2 for 24 h showed an
increase in green fluorescence compared to the control cells
indicating the disruption of the mitochondrial transmembrane
potential. After 48 h most of the mitochondria in the cells had
disrupted mitochondrial membrane potentials, as demonstrated
by the observation of mainly green fluorescence (Fig. 6C).
Altogether, these data indicate that mitochondrial apoptotic
pathways are involved in the mechanism of action of complex 2.
Previously we found that osmium arene complexes containing
picolinate chelating ligands accumulate in mitochondria and
Fig. 7 Eﬀects increasing concentrations of complex 2 on cell cycle distribution of A549 cells at the indicated times. Percentages of cells in G0/G1, S and
G2/M phase are indicated.
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are able to alter the morphology of the cristae.27 There are a
number of reports on transition metal complexes that can induce
cell death by acting on mitochondrial pathways; these include
ruthenium and iridium complexes and recently also similar obser-
vations for the triosmium cluster ([Os3(CO)10(m-H)(m-S)C9H6N]).
28–30
Interestingly, a family of lipophilic, cationic Au(I) complexes of
N-heterocyclic carbenes (NHCs) was shown to accumulate selec-
tively in the mitochondria and inhibit thioredoxin reductase.31
Targeting mitochondria in cancer cells appears to be a promis-
ing strategy, since enhanced mitochondrial stability and resis-
tance to apoptosis induction caused by the upregulation of pro-
survival proteins from the Bcl-2 family has been observed in a
variety of tumours.32 In addition, since these compounds act on
novel pathways compared to the commonly used chemo-
therapeutic drug CDDP, they offer promise in overcoming
CDDP-acquired tumour resistance and may therefore be bene-
ficial in combination treatment.
Cell cycle
The eﬀect of increasing concentrations of 2 on cell cycle
distribution of A549 cells after 24 and 48 h was investigated.
After 24 h, cells treated with 0.5 mM complex did not show a
considerable diﬀerence from the control cells. At higher con-
centrations, however, an increase in the amount of cells in the
S-phase was observed (Fig. 7). A subset of cells treated with
2.5 mM of 2 had undergone apoptosis, as indicated by the appear-
ance of a sub-G0/G1 peak. The biggest eﬀect was observed after 48 h
of exposure to 5 mM of 2 where a significant accumulation of the
cells in the S phase was observed.
S-phase cell cycle arrest in cancer cells may be advantageous
in providing diﬀerential toxicity since A549 cancer cells have
shorter doubling times compared to healthy cells. Several anti-
cancer agents are known to induce S-phase arrest in diﬀerent
types of human cancer cells, including cisplatin,33,34 mito-
mycin C,35,36 hydroxyurea,37 and the polyphenolic anticancer
agent resveratrol.38,39 Several anticancer agents are known to
inhibit topoisomerase activity and other key enzymes in DNA
duplication.40 It will be interesting to investigate further
mechanisms of S-phase arrest induced by 2.
Conclusions
In this work, three potent osmium arene phenylazopyridine
complexes were investigated for their modes of cellular uptake,
their cellular distribution, ability to cause cell cycle arrest,
induction of apoptosis, and involvement in mitochondrial
apoptotic pathways in A549 non-small cell lung cancer cells.
Iodido complexes 1 and 2 show potent anticancer activity in
the A549 cell line after 24 h incubation, that is ca. 6–10 more
potent than cisplatin. Furthermore, after 4 h of exposure, these
iodido complexes already showed high potency in the A549 cell
line, attributable to their rapid cellular uptake. The cell uptake
of the complexes did not correlate with their respective hydro-
phobicities, as measured by their log P values. This can be
explained by the temperature (energy)-dependent cellular uptake
of 2; only B25% of complex 2 was taken up by an energy-
independent mechanism (i.e. passive diffusion), in which
hydrophobicity can play a major role.
Drug eﬄux was observed after 48 and 72 h of drug exposure,
perhaps explaining why the IC50 values of the complexes are
highest after 24 h of exposure. All three compounds accumulate
in cell membranes to a large extent, consistent with the rapid
promotion of cell death by acting on mitochondrial pathways.
Indeed, compound 2 was able to cause cytochrome c release
and disrupt the mitochondrial membrane potential after 4 and
24 h of incubation at low doses. In addition, cells exposed to 2
accumulated in the S-phase in a concentration-dependent
manner. The data obtained here represent the first steps towards
understanding the mechanism of action of these novel osmium
arene complexes containing phenylazopyridine derivatives.
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